Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Interleukin-6 as a predictive factor of pathological response to FLOT regimen systemic treatment in locally advanced gastroesophageal junction (GEJ) or gastric cancer (GC) patients

Katarzyna Marcisz-Grzanka
* ORCID logo ,
Beata Kotowicz
,
Aleksandra Nowak
,
Mariola Winiarek
,
Malgorzata Fuksiewicz
ORCID logo ,
Maria Kowalska
,
Andrzej Tysarowski
,
Tomasz Olesinski
,
Jakub Palucki
,
Urszula Sulkowska
,
Agnieszka Kolasinska-Cwikla
,
Lucjan Stanislaw Wyrwicz
*
Version 1 : Received: 31 December 2023 / Approved: 2 January 2024 / Online: 2 January 2024 (07:25:05 CET)

A peer-reviewed article of this Preprint also exists.

Marcisz-Grzanka, K.; Kotowicz, B.; Nowak, A.; Winiarek, M.; Fuksiewicz, M.; Kowalska, M.; Tysarowski, A.; Olesinski, T.; Palucki, J.; Sulkowska, U.; Kolasinska-Cwikla, A.; Wyrwicz, L.S. Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients. Cancers 2024, 16, 757. Marcisz-Grzanka, K.; Kotowicz, B.; Nowak, A.; Winiarek, M.; Fuksiewicz, M.; Kowalska, M.; Tysarowski, A.; Olesinski, T.; Palucki, J.; Sulkowska, U.; Kolasinska-Cwikla, A.; Wyrwicz, L.S. Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients. Cancers 2024, 16, 757.

Abstract

Background: Perioperative treatment is a gold standard in locally advanced gastric cancer or GEJ cancer in western population. Unfortunately, the response rate after neoadjuvant chemotherapy (NAC) remains limited. Moreover, there are currently no biomarkers enabling an individual prediction of therapeutic efficacy. The aim of this study was identification of serum biomarkers of early response to NAC. Methods: We conducted this prospective study in the MSCNRIO, in Warsaw, Poland. A total of 71 patients and 15 healthy volunteers signed informed consent. Complete blood count, blood chemical tests, carcinoembryonic antigen (CEA) carcinoma antigen 125 (CA125), carcinoma an-tigen 19.9 (CA19.9), d-dimer, fibrinogen (F) were measured at baseline and before every cycle. Circulating tumour cells (CTCs) and interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) were measured in a pilot group of 40 patients at baseline and before cycle two (C2) and cycle three (C3). Results: Of all the measured parameters, only IL-6 serum level was statistically significant. The IL-6 level before C2 of chemotherapy was significantly decreased in complete pathological re-sponse (pCR) vs non-pCR group (3.71 pg/mL vs 7.63 pg/mL, p=0,004). In all patients with IL-6 levels below 5.0 pg/mL in C2, tumour regression TRG1a/1b according to Becker classification and ypN0 were detected in postoperative histopathological specimens. The IL-6 level before C1 of chemotherapy was significantly elevated in ypN+ vs ypN0 (7.69 pg/mL vs 2.89 pg/mL, p=0.022). Conclusions: The trial showed that elevated level of IL-6 prior to treatment and C2 might be a predictor of pathologic response to NAC.

Keywords

gastric cancer; gastroesophageal junction cancer; IL-6; FLOT regimen; predictive biomarker

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.